文献速递类风湿关节炎脊柱关节炎其他结缔组织病

研究特征对接受生物或合成抗风湿药治疗的炎性关节炎患者随机对照试验危害估计的影响:一项荟萃流行病学研究

Influence of study characteristics on harm estimates from randomised controlled trials in patients with inflammatory arthritis receiving biological or synthetic antirheumatic drugs: a meta-epidemiological study.
PubMed 文献 · Ann Rheum Dis · 2024-11-08

该荟萃流行病学研究检索MEDLINE上Cochrane系统评价及2015年4月以来发表的系统评价,纳入284项随机对照试验(97 607例炎性关节炎患者,490项比较),采用荟萃回归分析研究特征与危害指标的关系。结果显示多数研究特征不影响危害估计,但使用活性对照药时因不良事件退出相对风险更低(RRR 0.74,95%CI 0.58~0.94),入组要求炎症标志物升高时更高(RRR 1.25,95%CI 1.01~1.55)。

要点

  • 共纳入284项RCT、97 607例患者,490项比较用于主要分析。
  • 活性对照药试验因不良事件退出风险较低(RRR 0.74,95%CI 0.58~0.94)。
  • 入组要求炎症标志物升高者因不良事件退出风险较高(RRR 1.25,95%CI 1.01~1.55)。

核心结论

  • 多数研究特征不影响所报告的危害指标。
  • 观察到一种趋势:选择基线疾病活动度较高患者的试验,其因不良事件退出和严重不良事件的相对风险比较高,但总退出风险较低。

研究设计与样本

  • 荟萃流行病学研究,检索MEDLINE上所有Cochrane系统评价及2015年4月以来发表的系统评价。
  • 纳入284项随机对照试验(来自245篇系统评价),共97 607例炎性关节炎患者,490项比较进入主要分析。
  • 提取48项试验/患者特征,采用荟萃回归分析将危害的相对危险比(RRR)与研究特征相关联。

主要发现

  • 使用活性对照药时,因不良事件退出的相对风险较低(RRR 0.74,95%CI 0.58~0.94)。
  • 入组要求炎症标志物升高时,因不良事件退出的相对风险较高(RRR 1.25,95%CI 1.01~1.55)。
  • 荟萃回归分析提示,设定最小压痛/肿胀关节数和最大病程的入组标准可降低总退出风险。
  • 入组时既往使用过b/tsDMARDs可增加严重不良事件风险。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine the association between study characteristics and the harms reported in randomised controlled trials (RCTs) on biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in patients with inflammatory arthritis (IA). METHODS: We searched MEDLINE for all Cochrane reviews and for systematic reviews published since April 2015. RCTs were eligible if they included patients with IA receiving b/tsDMARD, compared with any comparator arm. Harms were evaluated based on number of withdrawals due to adverse events (WDdtAEs), total withdrawals (WDs), serious adverse events (SAEs) and deaths. Data were extracted for 48 trial/patient characteristics and meta-regression analyses were performed to relate the relative risk ratio (RRR) of harms to the trial characteristics. RESULTS: A total of 284 trials (from 245 reviews) with 97 607 patients were included, contributing 490 comparisons for the primary analysis. Overall, the relative risk of WDdtAEs was lower when trials used active comparators (RRR, 0.74 (95% CI 0.58 to 0.94)) and higher when requiring raised inflammatory markers at enrolment (RRR, 1.25 (1.01 to 1.55)). Our meta-regression analyses suggested that trials with eligibility criteria for minimum tender/swollen joint count and maximum disease duration decreased the risk of WDs, while previous b/tsDMARDs use at the time of enrolment increased the risk of SAEs. CONCLUSIONS: Most study characteristics do not affect the reported harm measures. However, a trend was observed where trials selecting patients with higher baseline disease activity found a higher risk ratio of WDdtAEs and SAEs, but also a lower risk of WDs, compared with trials not selecting patients with a high disease activity. PROSPERO REGISTRATION NUMBER: CRD42020171124.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Berg JI, Nielsen SM, Malm E, et al. Influence of study characteristics on harm estimates from randomised controlled trials in patients with inflammatory arthritis receiving biological or synthetic antirheumatic drugs: a meta-epidemiological study. Ann Rheum Dis. 2024. PMID: 39521451. doi:10.1136/ard-2024-226129

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。